PPP1R3C

Summary

PPP1R3C (protein phosphatase 1 regulatory subunit 3C, HGNC:9293) is a protein-coding gene on chromosome 10q23.32, encoding Protein phosphatase 1 regulatory subunit 3C (Q9UQK1). Acts as a glycogen-targeting subunit for PP1 and regulates its activity.

This gene encodes a carbohydrate binding protein that is a subunit of the protein phosphatase 1 (PP1) complex. PP1 catalyzes reversible protein phosphorylation, which is important in a wide range of cellular activities. The encoded protein affects glycogen biosynthesis by activating glycogen synthase and limiting glycogen breakdown by reducing glycogen phosphorylase activity. DNA hypermethylation of this gene has been found in colorectal cancer patients. The encoded protein also interacts with the laforin protein, which is a protein tyrosine phosphatase implicated in Lafora disease.

Source: NCBI Gene 5507 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 52 total
• MANE Select transcript: NM_005398

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9293
Approved symbol	PPP1R3C
Name	protein phosphatase 1 regulatory subunit 3C
Location	10q23.32
Locus type	gene with protein product
Status	Approved
Aliases	PTG
Ensembl gene	ENSG00000119938
Ensembl biotype	protein_coding
OMIM	602999
Entrez	5507

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000238994

RefSeq mRNA: 1 — MANE Select: NM_005398 NM_005398

CCDS: CCDS7416

Canonical transcript exons

ENST00000238994 — 2 exons

Exon	Start	End
ENSE00003992440	91632956	91633071
ENSE00003992444	91628442	91630866

Expression profiles

Bgee: expression breadth ubiquitous, 286 present calls, max score 99.83.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 28.5955 / max 1085.8300, expressed in 1239 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
110638	28.3750	1239
110636	0.1444	68
110637	0.0762	34

Top tissues by expression

297 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	99.83	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	99.75	gold quality
biceps brachii	UBERON:0001507	99.73	gold quality
vastus lateralis	UBERON:0001379	99.68	gold quality
triceps brachii	UBERON:0001509	99.64	gold quality
quadriceps femoris	UBERON:0001377	99.59	gold quality
body of tongue	UBERON:0011876	99.58	gold quality
gluteal muscle	UBERON:0002000	99.27	gold quality
deltoid	UBERON:0001476	99.12	gold quality
skeletal muscle tissue	UBERON:0001134	99.00	gold quality
tibialis anterior	UBERON:0001385	98.97	gold quality
esophagus squamous epithelium	UBERON:0006920	98.95	gold quality
vena cava	UBERON:0004087	98.94	gold quality
saphenous vein	UBERON:0007318	98.83	gold quality
calcaneal tendon	UBERON:0003701	98.81	gold quality
diaphragm	UBERON:0001103	98.78	gold quality
myocardium	UBERON:0002349	98.73	gold quality
left ventricle myocardium	UBERON:0006566	98.73	gold quality
epithelium of esophagus	UBERON:0001976	98.71	gold quality
cardiac muscle of right atrium	UBERON:0003379	98.71	gold quality
descending thoracic aorta	UBERON:0002345	98.24	gold quality
heart right ventricle	UBERON:0002080	98.22	gold quality
tendon	UBERON:0000043	98.17	gold quality
blood vessel layer	UBERON:0004797	97.94	gold quality
pharyngeal mucosa	UBERON:0000355	97.90	gold quality
popliteal artery	UBERON:0002250	97.76	gold quality
tibial artery	UBERON:0007610	97.76	gold quality
muscle tissue	UBERON:0002385	97.61	gold quality
trachea	UBERON:0003126	97.51	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	97.40	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): FOXA1, FOXA2, HIF1A

miRNA regulators (miRDB)

77 targeting PPP1R3C, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-520G-5P	99.99	66.76	658
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-144-3P	99.94	73.98	2698
HSA-MIR-4760-3P	99.93	70.50	2385
HSA-MIR-515-5P	99.92	69.82	2343
HSA-MIR-519E-5P	99.92	69.62	2358
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-506-3P	99.89	73.55	3057
HSA-MIR-5003-3P	99.85	69.29	2517
HSA-MIR-369-3P	99.85	70.52	2264
HSA-MIR-548AZ-5P	99.83	69.94	3230
HSA-MIR-548T-5P	99.83	69.91	3220
HSA-MIR-3681-5P	99.82	66.88	387
HSA-MIR-489-3P	99.80	66.46	839
HSA-MIR-4517	99.76	69.19	1867
HSA-MIR-6885-3P	99.75	70.36	3187
HSA-MIR-1179	99.71	68.70	1040
HSA-MIR-4729	99.69	72.18	4233
HSA-MIR-6887-3P	99.66	67.83	1778

Literature-anchored findings (GeneRIF, showing 7)

• phosphorylation of R5/PTG at Ser-8 by AMPK accelerates its laforin/malin-dependent ubiquitination and subsequent proteasomal degradation, which results in a decrease of its glycogenic activity. (PMID:19171932)
• Results demonstrated that HIF1 promotes glycogen accumulation through regulating PPP1R3C expression under hypoxia, which revealed a novel metabolic adaptation of cells to hypoxia. (PMID:20888814)
• Findings suggest that variations in PTG may condition the course of Lafora disease and establish PTG as a potential target for pharmacogenetic and therapeutic approaches. (PMID:21738631)
• detection of methylation of PPP1R3C alone or in combination with EFHD1 in plasma DNA showed high sensitivity and specificity in CRC detection, and may be useful detection method for CRC, especially for early-stage CRCs. (PMID:24861485)
• PPP1R3C, a novel hypermethylated gene in colorectal cancer, may play a critical role in cancer cell growth in association with glucose levels. (PMID:25846879)
• MiR-4461 Inhibits Tumorigenesis of Renal Cell Carcinoma by Targeting PPP1R3C. (PMID:32915648)
• AhRR and PPP1R3C: Potential Prognostic Biomarkers for Serous Ovarian Cancer. (PMID:37511212)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	ppp1r3cb	ENSDARG00000014554
danio_rerio	ppp1r3ca	ENSDARG00000071005
mus_musculus	Ppp1r3c	ENSMUSG00000067279
rattus_norvegicus	Ppp1r3c	ENSRNOG00000018494
drosophila_melanogaster	Gbs-70E	FBGN0036428
caenorhabditis_elegans		WBGENE00019211

Paralogs (6): PPP1R3F (ENSG00000049769), PPP1R3D (ENSG00000132825), PPP1R3A (ENSG00000154415), PPP1R3B (ENSG00000173281), PPP1R3G (ENSG00000219607), PPP1R3E (ENSG00000235194)

Protein

Protein identifiers

Protein phosphatase 1 regulatory subunit 3C — Q9UQK1 (reviewed: Q9UQK1)

Alternative names: Protein phosphatase 1 regulatory subunit 5, Protein targeting to glycogen

All UniProt accessions (1): Q9UQK1

UniProt curated annotations — full annotation on UniProt →

Function. Acts as a glycogen-targeting subunit for PP1 and regulates its activity. Activates glycogen synthase, reduces glycogen phosphorylase activity and limits glycogen breakdown. Dramatically increases basal and insulin-stimulated glycogen synthesis upon overexpression in a variety of cell types.

Subunit / interactions. Interacts with PPP1CC catalytic subunit of PP1 and associates with glycogen. Forms complexes with glycogen phosphorylase, glycogen synthase and phosphorylase kinase which is necessary for its regulation of PP1 activity. Also interacts with EPM2A/laforin.

Post-translational modifications. Ubiquitinated by NHLRC1/malin in a EPM2A/laforin-dependent manner.

Domain organisation. The N-terminal region is required for binding to PP1, the central region is required for binding to glycogen and the C-terminal region is required for binding to glycogen phosphorylase, glycogen synthase and phosphorylase kinase.

RefSeq proteins (1): NP_005389* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR005036	CBM21_dom	Domain
IPR017434	Pase-1_reg-su_3B/C/D_met	Family
IPR030683	PP1_3C	Family
IPR038175	CBM21_dom_sf	Homologous_superfamily
IPR050782	PP1_regulatory_subunit_3	Family

Pfam: PF03370

UniProt features (27 total): strand 13, mutagenesis site 4, helix 3, sequence variant 2, chain 1, domain 1, region of interest 1, turn 1, short sequence motif 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
7QF7	X-RAY DIFFRACTION	1.47
7QFA	X-RAY DIFFRACTION	2
7QFB	X-RAY DIFFRACTION	2.05
7QM2	X-RAY DIFFRACTION	2.69

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UQK1-F1	67.69	0.33

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Mutagenesis-validated functional residues (4):

Position	Phenotype
85	no effect on interaction with epm2a; when associated with a-87.
87	no effect on interaction with epm2a; when associated with a-85.
247	no interaction with epm2a; when associated with a-250.
250	no interaction with epm2a; when associated with a-247.

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-3322077	Glycogen synthesis
R-HSA-3785653	Myoclonic epilepsy of Lafora

MSigDB gene sets: 211 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_COLON_TUMORAL_MACROPHAGE_DN, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, GOBP_POLYSACCHARIDE_BIOSYNTHETIC_PROCESS, GOZGIT_ESR1_TARGETS_DN, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_DN, MENSE_HYPOXIA_UP, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, MCBRYAN_PUBERTAL_TGFB1_TARGETS_DN, LEE_LIVER_CANCER_CIPROFIBRATE_DN, FOXD3_01, GOBP_GENERATION_OF_PRECURSOR_METABOLITES_AND_ENERGY, MCBRYAN_PUBERTAL_BREAST_4_5WK_DN, UEDA_PERIFERAL_CLOCK, LI_WILMS_TUMOR_VS_FETAL_KIDNEY_1_UP, GOBP_REGULATION_OF_CARBOHYDRATE_METABOLIC_PROCESS

GO Biological Process (3): glycogen metabolic process (GO:0005977), glycogen biosynthetic process (GO:0005978), regulation of glycogen biosynthetic process (GO:0005979)

GO Molecular Function (7): protein serine/threonine phosphatase activity (GO:0004722), protein phosphatase 1 binding (GO:0008157), protein phosphatase binding (GO:0019903), protein-macromolecule adaptor activity (GO:0030674), glycogen binding (GO:2001069), protein binding (GO:0005515), molecular adaptor activity (GO:0060090)

GO Cellular Component (2): protein phosphatase type 1 complex (GO:0000164), cytosol (GO:0005829)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Glycogen metabolism	1
Glycogen storage diseases	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	2
cytoplasm	2
energy reserve metabolic process	1
glucan metabolic process	1
glycogen metabolic process	1
glucan biosynthetic process	1
glycogen biosynthetic process	1
regulation of glucan biosynthetic process	1
regulation of glycogen metabolic process	1
phosphoprotein phosphatase activity	1
protein phosphatase binding	1
phosphatase binding	1
protein binding	1
molecular adaptor activity	1
polysaccharide binding	1
molecular_function	1
protein serine/threonine phosphatase complex	1
cellular anatomical structure	1

Protein interactions and networks

STRING

790 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PPP1R3C	EPM2A	O95278	916
PPP1R3C	GYS1	P13807	885
PPP1R3C	PPP1R8	Q12972	848
PPP1R3C	NHLRC1	Q6VVB1	841
PPP1R3C	NFU1	Q9UMS0	765
PPP1R3C	TXNL1	O43396	720
PPP1R3C	EPM2AIP1	Q7L775	664
PPP1R3C	PYGM	P11217	600
PPP1R3C	PYGL	P06737	596
PPP1R3C	PYGB	P11216	594
PPP1R3C	AGL	P35573	547
PPP1R3C	GYS2	P54840	540
PPP1R3C	GBE1	Q04446	536
PPP1R3C	GYG2	O15488	532
PPP1R3C	GYG1	P46976	506

IntAct

33 interactions, top by confidence:

A	B	Type	Score
PPP1CB	PPP1R3C	psi-mi:“MI:0915”(physical association)	0.780
PPP1R3C	PPP1CB	psi-mi:“MI:0915”(physical association)	0.780
PPP1CA	PPP1R3C	psi-mi:“MI:0915”(physical association)	0.740
PPP1R3C	GYS1	psi-mi:“MI:0915”(physical association)	0.670
PPP1CC	PPP1R3C	psi-mi:“MI:0915”(physical association)	0.670
EPM2A	PPP1R3C	psi-mi:“MI:0915”(physical association)	0.570
PPP1R3C	EPM2A	psi-mi:“MI:0403”(colocalization)	0.570
PPP1R3C	EPM2A	psi-mi:“MI:0915”(physical association)	0.570
LXN	PPP1R3C	psi-mi:“MI:0915”(physical association)	0.560
LONRF1	PPP1R3C	psi-mi:“MI:0915”(physical association)	0.560
PPP1R3C	STBD1	psi-mi:“MI:0914”(association)	0.530
PCNA	PPP1R3C	psi-mi:“MI:0915”(physical association)	0.370
SGTA	PPP1R3C	psi-mi:“MI:0915”(physical association)	0.370
PPP1R3C	MYO1C	psi-mi:“MI:0914”(association)	0.350
PPP1CB	PPP1R3C	psi-mi:“MI:0915”(physical association)	0.000
LXN	PPP1R3C	psi-mi:“MI:0915”(physical association)	0.000
LONRF1	PPP1R3C	psi-mi:“MI:0915”(physical association)	0.000
PPP1CC	PPP1R3C	psi-mi:“MI:0915”(physical association)	0.000
PPP1CA	PPP1R3C	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (56): PPP1R3C (Two-hybrid), GYS2 (Affinity Capture-MS), GYS1 (Affinity Capture-MS), STBD1 (Affinity Capture-MS), TXNRD2 (Affinity Capture-MS), LACRT (Affinity Capture-MS), GYG1 (Affinity Capture-MS), EEA1 (Affinity Capture-MS), PPP1R3D (Affinity Capture-MS), GNG5 (Affinity Capture-MS), PPP1R3C (Two-hybrid), STBD1 (Affinity Capture-MS), PPP1R3D (Affinity Capture-MS), GYS1 (Affinity Capture-MS), LACRT (Affinity Capture-MS)

ESM2 similar proteins: A6QNP3, F1QJF4, F6Y9J3, O60308, P97874, Q02395, Q08D35, Q0VCR4, Q14B46, Q28E28, Q5BL87, Q5FWH3, Q5JTW2, Q5QNQ6, Q5R7T9, Q5U2R5, Q5XGX5, Q5XIZ9, Q60695, Q60949, Q6DDQ5, Q6GL23, Q6GL65, Q6GQ68, Q6IN01, Q6P950, Q7TMB3, Q803M0, Q80T23, Q80U87, Q812E4, Q86XI6, Q8BXR9, Q8C5W4, Q8C767, Q8C7M3, Q8GT06, Q8TDW5, Q8TE85, Q8VHQ7

Diamond homologs: A6QNP3, O95685, P40036, P40187, Q00756, Q0VCR4, Q16821, Q28E28, Q5BL87, Q5U2R5, Q6DDQ5, Q6GL23, Q6GQ68, Q6IN01, Q6P950, Q7TMB3, Q803M0, Q86XI6, Q8C767, Q99MR9, Q9UQK1, Q9VVY3, T1SFR8, B7ZBB8, P0C7L8, Q8BRJ4, Q9CW07, Q9H7J1, P28006, Q06216, Q6ZSY5, Q9JIG4, P07683

SIGNOR signaling

8 interactions.

A	Effect	B	Mechanism
NHLRC1	“down-regulates quantity by destabilization”	PPP1R3C	ubiquitination
PPP1R3C	up-regulates	GYS2	binding
PPP1R3C	up-regulates	GYS1	binding
PPP1R3C	up-regulates	PP1	binding
AMPK	“down-regulates quantity by destabilization”	PPP1R3C	phosphorylation
EPM2A	“up-regulates quantity by stabilization”	PPP1R3C	dephosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

52 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	51
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

67 predictions. Top by Δscore:

Variant	Effect	Δscore
10:91630862:TCATT:T	acceptor_gain	1.0000
10:91630863:CATT:C	acceptor_gain	1.0000
10:91630863:CATTC:C	acceptor_gain	1.0000
10:91630865:TT:T	acceptor_gain	1.0000
10:91630867:C:CC	acceptor_gain	1.0000
10:91630864:ATT:A	acceptor_gain	0.9900
10:91630872:A:AC	acceptor_gain	0.9900
10:91630872:A:C	acceptor_gain	0.9900
10:91630875:C:CT	acceptor_gain	0.9900
10:91630876:A:T	acceptor_gain	0.9900
10:91632952:CTA:C	donor_loss	0.9900
10:91632955:C:T	donor_loss	0.9900
10:91632954:A:AC	donor_gain	0.9700
10:91632955:C:CC	donor_gain	0.9700
10:91630864:ATTC:A	acceptor_gain	0.9400
10:91630865:TTC:T	acceptor_gain	0.9400
10:91630866:TCT:T	acceptor_gain	0.9400
10:91630867:CTGG:C	acceptor_gain	0.9400
10:91630868:T:G	acceptor_gain	0.9300
10:91632952:CTACC:C	donor_gain	0.9300
10:91632953:TACCT:T	donor_gain	0.9300
10:91632954:ACCTG:A	donor_gain	0.8700
10:91632955:CCTG:C	donor_gain	0.8200
10:91630864:A:C	acceptor_gain	0.7800
10:91632955:CC:C	donor_gain	0.7700
10:91632900:C:A	donor_gain	0.6600
10:91631401:T:TA	donor_gain	0.6500
10:91631402:C:A	donor_gain	0.6300
10:91632899:T:TA	donor_gain	0.6300
10:91630869:G:C	acceptor_gain	0.6100

AlphaMissense

2119 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:91630321:C:G	R187P	0.999
10:91630620:A:C	F87L	0.999
10:91630620:A:T	F87L	0.999
10:91630622:A:G	F87L	0.999
10:91630233:G:C	F216L	0.998
10:91630233:G:T	F216L	0.998
10:91630235:A:G	F216L	0.998
10:91630304:A:G	W193R	0.998
10:91630304:A:T	W193R	0.998
10:91630363:A:T	V173D	0.998
10:91630370:C:A	G171W	0.998
10:91630411:A:T	V157D	0.998
10:91630621:A:G	F87S	0.998
10:91630180:A:G	F234S	0.997
10:91630278:A:C	C201W	0.997
10:91630302:C:A	W193C	0.997
10:91630302:C:G	W193C	0.997
10:91630330:A:T	V184D	0.997
10:91630369:C:T	G171E	0.997
10:91630467:G:C	F138L	0.997
10:91630467:G:T	F138L	0.997
10:91630469:A:G	F138L	0.997
10:91630614:G:C	D89E	0.997
10:91630614:G:T	D89E	0.997
10:91630618:G:T	A88D	0.997
10:91630621:A:C	F87C	0.997
10:91630176:G:C	C235W	0.996
10:91630227:A:C	F218L	0.996
10:91630227:A:T	F218L	0.996
10:91630228:A:G	F218S	0.996

dbSNP variants (sampled 300 via entrez): RS1000013909 (10:91633256 G>C,T), RS1000087325 (10:91633492 C>A,G,T), RS1001480145 (10:91628175 G>A), RS1002220190 (10:91634127 C>T), RS1002252752 (10:91634441 G>C), RS1003073496 (10:91629349 T>A,C), RS1003464422 (10:91630985 C>G,T), RS1003577974 (10:91628051 C>T), RS1003588476 (10:91628303 G>A), RS1003721353 (10:91634557 C>A,G), RS1003863200 (10:91633074 G>A,C,T), RS1003928317 (10:91628988 T>C), RS1004341061 (10:91633190 G>T), RS1004665904 (10:91628224 G>A), RS1005106102 (10:91630702 G>A,C,T)

Disease associations

OMIM: gene MIM:602999 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

101 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression, increases expression	5
Benzo(a)pyrene	decreases expression, increases methylation	4
Estradiol	affects cotreatment, increases expression, decreases expression	4
Cyclosporine	decreases expression, affects cotreatment	4
bisphenol A	affects expression, increases expression	2
trichostatin A	affects cotreatment, affects expression, affects methylation, increases expression	2
sodium arsenite	affects cotreatment, decreases expression, increases abundance, increases expression	2
cobaltous chloride	increases expression	2
Acetaminophen	increases expression, affects cotreatment	2
Oxygen	increases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Silicon Dioxide	decreases expression	2
Tetrachlorodibenzodioxin	increases expression, decreases expression, affects cotreatment	2
Tobacco Smoke Pollution	increases expression, decreases expression	2
Tretinoin	decreases expression, increases expression	2
Triclosan	decreases expression	2
Aflatoxin B1	affects expression, decreases expression, decreases methylation	2
tert-Butylhydroperoxide	affects expression, decreases expression	2
Particulate Matter	increases abundance, increases expression, decreases expression	2
aristolochic acid I	decreases expression	1
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
tungsten carbide	affects binding, increases expression	1
methylmercuric chloride	increases expression	1
2-methyl-4-isothiazolin-3-one	increases expression	1
methylparaben	increases expression	1
sulforaphane	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
nickel chloride	increases expression	1
zinc chromate	increases abundance, increases expression	1
manganese chloride	affects cotreatment, decreases expression, increases abundance	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2BX	Abcam HeLa PPP1R3C KO	Cancer cell line	Female

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer